Based on the key measurements obtained from IRIDEX's financial statements, IRIDEX may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, IRIDEX's Non Current Liabilities Total is fairly stable compared to the past year. Other Liabilities is likely to rise to about 14.3 M in 2025, despite the fact that Other Current Liabilities is likely to grow to (2.6 M). Key indicators impacting IRIDEX's financial strength include:
The financial analysis of IRIDEX is a critical element in measuring its lifeblood. Investors should not minimize IRIDEX's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Understanding current and past IRIDEX Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of IRIDEX's financial statements are interrelated, with each one affecting the others. For example, an increase in IRIDEX's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in IRIDEX's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IRIDEX. Check IRIDEX's Beneish M Score to see the likelihood of IRIDEX's management manipulating its earnings.
IRIDEX Stock Summary
IRIDEX competes with STRATA Skin, Aurora Spine, Elutia, Sight Sciences, and ImmuCell. IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. Iridex Cp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of IRIDEX. It measures of how well IRIDEX is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money IRIDEX brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money IRIDEX had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what IRIDEX has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining IRIDEX's current stock value. Our valuation model uses many indicators to compare IRIDEX value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IRIDEX competition to find correlations between indicators driving IRIDEX's intrinsic value. More Info.
IRIDEX is rated below average in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . At this time, IRIDEX's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IRIDEX's earnings, one of the primary drivers of an investment's value.
IRIDEX Systematic Risk
IRIDEX's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. IRIDEX volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on IRIDEX correlated with the market. If Beta is less than 0 IRIDEX generally moves in the opposite direction as compared to the market. If IRIDEX Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one IRIDEX is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of IRIDEX is generally in the same direction as the market. If Beta > 1 IRIDEX moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in IRIDEX Stock are looking for potential investment opportunities by analyzing not only static indicators but also various IRIDEX's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of IRIDEX growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of IRIDEX help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of IRIDEX. We use our internally-developed statistical techniques to arrive at the intrinsic value of IRIDEX based on widely used predictive technical indicators. In general, we focus on analyzing IRIDEX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build IRIDEX's daily price indicators and compare them against related drivers.
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.